Immunic (IMUX) Competitors

In the previous week, Oculis had 2 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat Oculis' score of 0.78 indicating that Immunic is being referred to more favorably in the news media.

Oculis currently has a consensus price target of $38.33, suggesting a potential upside of 196.47%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 223.84%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Oculis.

Immunic has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Immunic's return on equity.

22.3% of Oculis shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunic has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Oculis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Zevra Therapeutics had 2 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat Zevra Therapeutics' score of 0.89 indicating that Immunic is being referred to more favorably in the media.

Immunic presently has a consensus price target of $47.57, suggesting a potential upside of 223.84%. Zevra Therapeutics has a consensus price target of $29.29, suggesting a potential upside of 124.24%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Zevra Therapeutics.

Zevra Therapeutics has a net margin of 101.58% compared to Immunic's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Immunic's return on equity.

Zevra Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

51.8% of Immunic shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Immunic has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Immunic's return on equity.

Immunic has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunic has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Immunic currently has a consensus price target of $47.57, indicating a potential upside of 223.84%. ARS Pharmaceuticals has a consensus price target of $28.20, indicating a potential upside of 270.57%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Immunic.

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat ARS Pharmaceuticals' score of 0.57 indicating that Immunic is being referred to more favorably in the media.

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 111.79%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 223.84%. Given Immunic's higher probable upside, analysts plainly believe Immunic is more favorable than Aclaris Therapeutics.

Immunic has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Immunic's return on equity.

Aclaris Therapeutics has higher revenue and earnings than Immunic. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 1.89 beat Immunic's score of 0.93 indicating that Aclaris Therapeutics is being referred to more favorably in the media.